NasdaqGS - Nasdaq Real Time Price USD
AbCellera Biologics Inc. (ABCL)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 7:47 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 7 | 7 | 5 |
| Avg. Estimate | -0.15 | -0.16 | -0.58 | -0.69 |
| Low Estimate | -0.17 | -0.18 | -0.64 | -0.84 |
| High Estimate | -0.13 | -0.13 | -0.52 | -0.46 |
| Year Ago EPS | -0.1 | -0.17 | -0.51 | -0.58 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 9 | 7 |
| Avg. Estimate | 7.95M | 8.24M | 33.6M | 48.61M |
| Low Estimate | 5.1M | 5.1M | 27.48M | 22M |
| High Estimate | 10.62M | 11.76M | 40M | 94M |
| Year Ago Sales | 11.84M | 9.18M | 38.02M | 33.6M |
| Sales Growth (year/est) | -32.90% | -10.20% | -11.60% | 44.70% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.13 | -0.17 | -0.14 |
| EPS Actual | -0.1 | -0.17 | -0.14 | -0.13 |
| Difference | 0.03 | -0.04 | 0.03 | 0.01 |
| Surprise % | 23.10% | -30.80% | 17.60% | 7.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.16 | -0.58 | -0.69 |
| 7 Days Ago | -0.15 | -0.16 | -0.58 | -0.69 |
| 30 Days Ago | -0.17 | -0.17 | -0.6 | -0.74 |
| 60 Days Ago | -0.17 | -0.17 | -0.6 | -0.74 |
| 90 Days Ago | -0.14 | -0.15 | -0.57 | -0.62 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ABCL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -50.00% | -- | -- | 3.60% |
| Next Qtr. | 5.90% | -- | -- | 7.90% |
| Current Year | -13.70% | -- | -- | 2.50% |
| Next Year | -19.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 10.00% | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Downgrade | Benchmark: Buy to Hold | 8/20/2024 |
| Maintains | Keybanc: Overweight to Overweight | 7/11/2024 |
| Maintains | Keybanc: Overweight to Overweight | 5/8/2024 |
| Upgrade | Benchmark: Hold to Buy | 2/22/2024 |
| Maintains | Stifel: Buy to Buy | 2/21/2024 |
| Initiated | Keybanc: Overweight | 12/5/2023 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
20.67
-1.94%
DNA Ginkgo Bioworks Holdings, Inc.
8.92
+0.45%
RXRX Recursion Pharmaceuticals, Inc.
6.76
-2.59%
EDIT Editas Medicine, Inc.
3.7600
+11.90%
BEAM Beam Therapeutics Inc.
23.15
-2.11%
CRBU Caribou Biosciences, Inc.
1.9700
-1.50%
CRSP CRISPR Therapeutics AG
48.51
-0.84%
IOVA Iovance Biotherapeutics, Inc.
9.92
-3.12%
PRME Prime Medicine, Inc.
4.3700
-0.23%
SEEL Seelos Therapeutics, Inc.
1.1300
+11.88%